Supplement Facts |
|||
|
Serving Size |
2 Tablets |
||
|
Servings Per Container |
60 |
||
|
Amount Per Serving |
% Daily Value |
||
|
Folic Acid |
200 |
mcg |
50% |
|
Vitamin B-12 (Cyanocobalamin) |
100 |
mcg |
1667% |
|
Calcium (Total) |
205 |
mg |
21% |
|
Ipriflavone |
300 |
mg |
* |
|
Pyridoxal 5-Phosphate |
15 |
mg |
* |
|
Vanadium (as Vanadyl Sulfate) |
50 |
mcg |
* |
|
*Daily Value not established |
|||
INGREDIENTS: Calcium Citrate Malate Carbonate Complex, Ipriflavone, Dicalcium Phosphate, Stearic Acid, Silica, Microcrystalline Cellulose, Pyridoxal 5-Phosphate, Croscarmellose Sodium, Magnesium Stearate, Vitamin B-12 (Cyanocobalamin), Vanadyl Sulfate, Folic Acid, and PhytoZyme™ proprietary blend (Bromelain, Papain, Aloe Vera, Alfalfa, Parsley, and vegetable and fruit concentrates from Carrots, Broccoli, Spinach, Cauliflower, Asparagus, Celery, Beet, Chili Pepper, Green Bean, Pea, Sweet Potato, Cucumber, Pumpkin, Snow Pea, Tomato, Zucchini, Lima Beans, Mushroom, Banana, Cantaloupe, Cranberry, Guava, Lemon, Mango, Orange, Papaya, Peach, Pineapple and Grapefruit).
DIRECTIONS: Two tablets twice a day.
Formulated in the exclusive PhytoZyme™ base of plant enzymes for bioavailability and over 30 synergistic fruit, vegetable and herbal concentrates for "extra" phytonutrient cofactors.
Contains no artificial preservatives, sugar, starch, caffeine, salt, wheat, gluten, yeast, corn, milk, egg, shellfish, soya derivatives, artificial sweetening, flavoring or coloring agents.
Contains no ingredients from animal sources.
This product is not tested on animals.
References:
1. Tsutsumi N, Kawashima K, Nagata H, et al. Effects of KCA-098 on bone metabolism: comparison with those of ipriflavone. Jpn J Pharmacol 1994; 65
2. Benvenuti S, Tanini A, Frediani U, et al. Effects of ipriflavone and its metabolites on a clonal osteoblastic cell line. J Bone Miner Res 1991; 6
3. Agnusdei D, Gennari C, Bufalino L. Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone. Osteoporosis Int 1995; 5
4. Sato Y. Abnormal bone and calcium metabolism in patients after stroke. Arch Phys Med Rehabil 2000 Jan; 81 (1)
5. Bostom AG, Silbershatz IH, Rosenberg IH, et al. Non-fasting plasma total homocysteine levels and all cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med 1999; 159:1077-80
6. Amano R, Enomoto S, Nobuta M, et al. Bone uptake of vanadium in mice: simultaneous tracing of V, Se, Sr, Y, Zr, Ru, and Rh using a radioactive multitracer. J Trace Elem Med Biol 1996 Sep;10(3):145-8.
7. Agnusdei D, Bufalino L. Efficacy of ipriflavone in established osteoporosis and long-term safety. Calcif Tissue Int 1997;61:S23-S27
8. Krumdieck CL, Prince CW. Mechanisms of homocysteine toxicity on connective tissues: implications for the morbidity of aging. J Nutr 2000 Feb;130(2S /syook):354S-368S
9. Miller J, Smith D, Flora L, et al. Calcium absorption from calcium carbonate and a new form of calcium (CCM) in healthy male and female adolescents. Am J Clin Nutr 1988;48:1291–4.*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Copyright © & Disclaimer 1995-2010 - SJS Distributors , USA. All Rights Reserved.- Please Click Here!